Dystonia

• Basal ganglia circuit abnormality: The primary pathophysiology centers on dysregulation of the direct and indirect motor pathways within the basal ganglia. In healthy individuals, the direct pathway (striatum → globus pallidus internus/substantia nigra pars reticulata) facilitates movement, while the indirect pathway (striatum → globus pallidus externus → subthalamic nucleus) inhibits unwanted movements. In dystonia, there is relative overactivity of the indirect inhibitory pathway and reduced GABAergic output from the globus pallidus internus, resulting in excessive inhibition of thalamocortical circuits and paradoxical involuntary muscle activation. Loss of normal sensorimotor gating allows competing motor programs to activate simultaneously.

• Loss of inhibitory control and surround inhibition: Normal motor execution requires selective activation of agonist muscles combined with inhibition of antagonist muscles through a mechanism called surround inhibition. In dystonia, this inhibitory surround is diminished, allowing co-contraction of agonist-antagonist muscle pairs and overflow of motor activity to adjacent uninvolved muscles. Electrophysiologic studies demonstrate reduced intracortical inhibition and abnormal reciprocal inhibition between opposing muscles.

• Sensorimotor integration dysfunction: Dystonia involves abnormal processing of proprioceptive and somatosensory information at cortical and subcortical levels. The basal ganglia normally integrate sensory feedback to refine ongoing movements; loss of this integration permits abnormal sensorimotor plasticity. This explains why dystonic symptoms often worsen with focused attention on the affected body part and improve with sensory tricks (geste antagoniste)—light touch or pressure applied to the dystonic region that resets abnormal sensory input processing.

• Cellular mechanisms in genetic dystonia: Mutations in genes such as TOR1A (DYT1), THAP1 (DYT6), and GCH1 (DYT5) result in impaired protein function affecting synaptic plasticity, transcription regulation, and neurotransmitter synthesis. For example, TOR1A encodes torsinA, an AAA+ ATPase localized to the endoplasmic reticulum and nuclear envelope involved in protein folding and maintenance of synaptic architecture. Loss of normal torsinA function leads to altered synaptic connectivity and reduced inhibitory GABA signaling.

Primary Dystonia (Genetic)

• DYT1 dystonia: Autosomal dominant TOR1A mutation; early-onset (typically age <50, often childhood-adolescence); predominantly limb-onset with potential generalization; 30-40% penetrance; most common monogenic dystonia
• DYT6 dystonia: Autosomal dominant THAP1 mutation; cranial/cervical onset (dystonic laryngeal stridor, facial grimacing); rapid progression; no family history in ~50% (de novo mutations)
• DYT5 dystonia-parkinsonism: Autosomal dominant or recessive GCH1 mutations; dopa-responsive dystonia; childhood-onset leg dystonia; parkinsonism in some; dramatic response to levodopa distinguishes this treatable form
• X-linked dystonia-parkinsonism (DYT3): TAF1 mutations; progressive dystonia-parkinsonism; onset typically 30-40 years in Filipino populations
• Other primary dystonias: DYT2 (autosomal recessive, rare), DYT7 (cervical dystonia, later-onset), DYT13 (segmental, heterogeneous presentations)

Secondary Dystonia (Acquired)

• Medications: Antipsychotics (haloperidol, risperidone) and metoclopramide cause acute dystonic reactions or tardive dystonia; mechanism involves dopamine blockade and sensitization of basal ganglia neurons
• Basal ganglia structural lesions: Stroke, tumor, arteriovenous malformation, or trauma affecting putamen, globus pallidus, or subthalamic nucleus
• Neurodegenerative diseases: Parkinson's disease (dystonia as early sign or levodopa-related), progressive supranuclear palsy, Huntington's disease, Wilson's disease, pantothenate kinase-associated neurodegeneration (PKAN), neuroacanthocytosis
• Metabolic/toxic disorders: Carbon monoxide poisoning (delayed parkinsonism-dystonia syndrome), manganese toxicity, hypoxia, hypoparathyroidism
• Infections: Post-encephalitic dystonia (historically after influenza; now rare), post-infectious autoimmune dystonia
• Cerebral palsy: Dystonia is the predominant movement disorder in 10-15% of patients with cerebral palsy
• Traumatic brain injury: Post-traumatic dystonia develops months to years after injury
• Psychogenic dystonia: Diagnosis of exclusion requiring inconsistency with known patterns, non-anatomic distribution, rapid onset, distractibility, or presence of other non-organic signs; accounts for 5-10% of dystonia cases

Risk Factors

• Family history: Strong predictor for primary genetic dystonia
• Age of exposure to dystonia-inducing medications: Higher risk with chronic antipsychotic use, particularly in younger patients
• Specific occupations: Musician's dystonia and writer's cramp show task-specific patterns
• Trauma or focal peripheral injury: Can trigger dystonia in affected limb months to years later (post-traumatic or post-traumatic dystonia)

Cardinal Features

• Involuntary sustained muscle contractions: Muscles maintain abnormal contraction for variable duration (seconds to minutes), distinguishing dystonia from tremor (rhythmic) or chorea (irregular)
• Abnormal postures: Sustained twisting or deviation of affected body parts; classic examples include foot inversion (equinovarus), neck deviation (torticollis), facial grimacing (oculogyric crisis, blepharospasm), or hand dystonia with fingers extended and wrist flexed
• Repetitive movements: Dystonic movements appear semi-purposeful but are involuntary; can take form of oscillations or writhing movements distinct from choreic movements
• Sensory tricks (geste antagoniste): Patient-discovered maneuvers that improve dystonia through light touch or pressure applied to affected body part (e.g., touching chin to relieve cervical dystonia); highly specific for dystonia; mechanism involves resetting abnormal proprioceptive processing
• Action-induced worsening: Dystonia often emerges or worsens with intentional movement toward the affected body part; conversely, dystonia may disappear at rest or with different movements
• Diurnal variation: Morning improvement and evening worsening are characteristic, particularly in dopa-responsive dystonia
• Lack of cognitive decline: Dystonia alone does not cause dementia; presence of cognitive decline suggests secondary dystonia or alternate diagnosis

Anatomic Distribution Patterns

• Focal dystonia: Involves single body region (blepharospasm, cervical dystonia, writer's cramp, oromandibular dystonia, laryngeal dystonia)
• Segmental dystonia: Two or more contiguous body regions (e.g., cervical + brachial, cranial + cervical)
• Multifocal dystonia: Non-contiguous body regions affected (e.g., cervical + lower extremity)
• Generalized dystonia: Trunk plus at least two other body regions; typically indicates early-onset primary dystonia (DYT1) or severe secondary dystonia
• Hemidystonia: Unilateral involvement strongly suggests secondary dystonia from contralateral basal ganglia lesion

Physical Examination Findings

• Posture assessment at rest and with action: Observe for sustained abnormal positioning; have patient write, walk, or perform task-specific movements to elicit dystonia
• Gait abnormality: Dystonic gait may show circumduction (avoidance of dystonic limb), equinovarus positioning, or trunk deviation
• Head/neck exam: Torticollis (abnormal head deviation), anterocollis, retrocollis, or laterocollis; assess cervical range of motion and pain
• Cranial nerve findings: Blepharospasm (forceful eye closure), oculogyric crisis (sustained upward deviation of eyes), jaw deviation, lingual dystonia (tongue protrusion or deviation)
• Limb examination: Pronation-extension dystonia of arms, finger extension with wrist flexion, clenched fist at rest, toe clawing
• Secondary signs: Muscle hypertrophy from chronic contractions; skin changes from sweating; dystonic tremor (low-amplitude, irregular, present during sustained posture)
• Absence of spasticity, pyramidal signs, or rigidity (unless secondary dystonia with additional pathology)
• Normal cognition, normal eye movements (except task-specific dystonia), normal reflexes (except in some forms like dopa-responsive dystonia which may have hyperreflexia)

Temporal Characteristics

• Age of onset: Early-onset primary dystonia (age <26) more likely to generalize; late-onset (age >26) typically focal and less progressive
• Progression: Early-onset may rapidly progress to generalized form over months to years; late-onset focal dystonia usually remains focal
• Symptom fluctuation: Worsens with stress, fatigue, and emotional distress; improves with sleep and relaxation

Clinical Diagnosis

• Direct observation of sustained muscle contraction during examination
• Reproduction of dystonia with repetitive movements or specific tasks
• Presence of sensory tricks or relief with specific positions
• Exclusion of alternative explanations (tremor, chorea, myoclonus, spasticity)

Diagnostic Approach: Primary vs. Secondary Dystonia

• Early age of onset (<30 years), family history, focal or generalized pattern, no cognitive decline, no preceding structural brain imaging abnormalities → suggests primary dystonia
• Late age of onset (>50 years), acute presentation, hemidystonia, progressive cognitive decline, prior exposure to antipsychotics, evidence of trauma or stroke, atypical features → suggests secondary dystonia requiring investigation

Laboratory Testing

• Serum ceruloplasmin and 24-hour urine copper: Essential screening test in any patient with dystonia and atypical features, cognitive decline, or Kayser-Fleischer rings (Wilson's disease)
• Levodopa trial: All patients with early-onset dystonia should receive formal levodopa challenge (L-dopa 5 mg/kg/day divided in 3 doses for minimum 3 months) to identify dopa-responsive dystonia (DYT5); dramatic response (>90% improvement) is diagnostic
• Plasma phenylalanine: Consider in childhood-onset dystonia with developmental delay
• Lactate level (resting and post-exercise): May suggest mitochondrial cytopathy in presence of other features
• Standard metabolic panel, thyroid function tests, calcium: Rule out metabolic causes in secondary dystonia

Neuroimaging

• MRI brain: Indicated in secondary dystonia or atypical presentations
• May reveal basal ganglia iron accumulation (hyperintense T2/susceptibility-weighted signal in globus pallidus or substantia nigra) in neurodegeneration with brain iron accumulation (NBIA) syndromes
• Shows structural lesions (stroke, tumor, AVMs) in symptomatic secondary dystonia
• Usually normal in primary genetic dystonia (DYT1, DYT6); normal imaging helps support primary dystonia diagnosis
• Look for cavitation or signal changes in carbon monoxide poisoning

• CT brain: Less sensitive but may show calcification (basal ganglia calcification in hypoparathyroidism)

• Dopamine transporter (DaT) imaging or PET: Not routinely performed but may help differentiate dystonia from parkinsonism or assess dopamine system integrity

Genetic Testing

• Gene sequencing: Increasingly available and valuable for confirmed diagnosis
• TOR1A (DYT1): First-line testing in early-onset generalized or segmental dystonia, particularly with limb onset; 30-40% penetrance means negative family history does not exclude diagnosis
• THAP1 (DYT6): Consider in familial dystonia with cranial or cervical onset
• GCH1 (DYT5): Test in childhood-onset dystonia before or during levodopa trial (dramatic response nearly diagnostic)
• TAF1 (DYT3): Consider in Filipino patients with dystonia-parkinsonism
• Comprehensive panel testing: Increasingly used for atypical presentations given improved cost and availability

• Limitations: Many primary dystonias have incomplete penetrance and variable expressivity; genetic testing provides confirmation but does not change management in most cases

Specialized Neurophysiology

• Electromyography (EMG): Demonstrates sustained motor unit action potentials in dystonic muscles; shows lack of silent period between agonist and antagonist muscles; helps distinguish dystonia from other movement disorders
• Surface electromyography: Shows co-contraction of antagonist muscles during attempted movement
• Magnetic resonance spectroscopy: Research tool; may show altered GABA and glutamate in basal ganglia circuits

Diagnostic Exclusion of Mimics

• Essential tremor: Rhythmic oscillation, not sustained contraction; worse with action and intentional posture maintenance; responds to beta-blockers
• Choreiform movements: Irregular, non-repetitive, dance-like, unpredictable in timing and location
• Myoclonus: Brief, shock-like contractions; not sustained; different EMG pattern
• Spasticity: Velocity-dependent resistance; present with passive range of motion; history of upper motor neuron lesion
• Tics: Suppressible, preceded by premonitory sensation, waxing-waning course; different anatomic patterns
• Parkinsonism: Bradykinesia, rigidity, tremor; responds to dopamine agonists (not present in pure dystonia)

Initial Management and Patient Education

• Counseling: Explain that dystonia is a movement disorder, not psychogenic; reassure regarding benign prognosis (primary dystonia does not reduce lifespan or cause cognitive decline)
• Identify and avoid triggers: Stress, fatigue, focusing attention on affected body part
• Physical and occupational therapy: Beneficial for postural education, ergonomic modifications, development of compensatory strategies, and task-specific training; referral to therapists experienced with dystonia
• Sensory tricks: Reinforce patient-discovered maneuvers and systematize them (e.g., chin touch for cervical dystonia, sensory input to affected hand for writer's cramp)

Pharmacologic Treatment

First-Line: Botulinum Toxin

• Mechanism: Presynaptic blockade of acetylcholine release at neuromuscular junction; prevents muscle contraction for 12-16 weeks; irreversible block until new neuromuscular junctions form
• Indications: Gold standard for focal and segmental dystonia (cervical dystonia, blepharospasm, oromandibular dystonia, laryngeal dystonia, writer's cramp); most evidence-based treatment for these forms
• Efficacy: 60-85% of patients experience significant benefit; requires expertise in localization and dosing (measured in Mouse Units [MU])
• Administration: Injected directly into dystonic muscles under electromyographic guidance or ultrasound guidance; effects begin at 3-7 days, peak at 2-4 weeks
• Dosing: Variable by muscle group and individual response; typical cervical dystonia doses 120-300 MU; initial treatment may require adjustment
• Repeat injections: Required every 3-

Complications of the disease

• **Status dystonicus (dystonic storm): relentless generalized dystonic spasms, most often in DYT1 or secondary generalized dystonia triggered by infection, drug withdrawal, or interruption of therapy. Sustained contraction causes rhabdomyolysis with markedly elevated CK, myoglobinuric acute kidney injury, hyperthermia, and bulbar/respiratory muscle failure. This is a neurologic emergency** requiring ICU admission, sedation, and aggressive hydration.
• Fixed contractures and secondary orthopedic injury: chronic co-contraction shortens muscle and tendon, converting a correctable posture into a fixed one; in long-standing cervical dystonia, repetitive torsion accelerates cervical spondylosis and can produce cervical myelopathy (hyperreflexia, gait change, sensory level) — an urgent finding.
• Functional blindness in blepharospasm: forced orbicularis oculi closure prevents eye opening despite intact visual pathways.
• Aspiration: oromandibular, lingual, and laryngeal dystonia impair swallow coordination; recurrent pneumonia or weight loss signals it.
• Pain, depression, and social withdrawal: chronic muscle overuse and visible disfigurement; depression is common and often underdiagnosed.

Complications of treatment

• Botulinum toxin: excess local weakness is dose- and diffusion-related — ptosis and diplopia after blepharospasm injection, dysphagia and neck extensor weakness after cervical injection (the most common adverse effect there). The FDA carries a boxed warning for distant spread producing generalized weakness, dysphagia, and respiratory compromise — an emergency. Neutralizing antibodies cause secondary nonresponse after previously effective injections.
• Trihexyphenidyl/anticholinergics: central and peripheral muscarinic blockade → confusion, blurred vision, urinary retention; poorly tolerated in older adults.
• Intrathecal baclofen: catheter kink or pump failure causes acute baclofen withdrawal — fever, rigidity, rebound dystonia, and altered mentation mimicking neuroleptic malignant syndrome; an emergency treated with baclofen reinstitution.
• Deep brain stimulation: perioperative intracranial hemorrhage, hardware infection, and lead fracture; chronic pallidal stimulation may induce bradykinesia and gait freezing. Abrupt battery depletion can precipitate status dystonicus.
• Tetrabenazine carries an FDA boxed warning for depression and suicidality.

• **Sensory trick (geste antagoniste) is the giveaway**: a stem describing a patient whose head turning resolves when she rests a finger on her chin is describing dystonia, not tremor, tic, or spasticity. It is highly specific and reflects abnormal sensorimotor gating, not distractibility.
• Any childhood- or adolescent-onset dystonia gets a levodopa trial: dopa-responsive dystonia (Segawa disease, GCH1/DYT5) presents as gait-onset leg dystonia with diurnal variation — normal in the morning, disabling by evening — and is classically misdiagnosed as spastic diplegic cerebral palsy. The dramatic, sustained response to low-dose levodopa is both diagnostic and definitive therapy. Missing this is the single most testable error.
• DYT1 = TOR1A GAG deletion: autosomal dominant with only ~30% penetrance (so no family history does not exclude it), enriched in Ashkenazi Jewish ancestry, childhood limb onset that generalizes. It also has the best response to bilateral globus pallidus internus DBS when medically refractory.
• Hemidystonia means look for a lesion: unilateral dystonia implies a contralateral basal ganglia structural insult — the next step is brain MRI, not genetic testing.
• Screen for Wilson disease in any patient under about 40 with new dystonia: ceruloplasmin, 24-hour urine copper, and slit-lamp exam for Kayser-Fleischer rings; AASLD guidance supports this workup because the disease is treatable and fatal if missed.
• Acute dystonic reaction after a dopamine blocker (haloperidol, metoclopramide, prochlorperazine) presents within hours to days as torticollis, trismus, or oculogyric crisis; the best next step is an anticholinergic or antihistamine — IM/IV benztropine or diphenhydramine — with rapid resolution.
• Common distractor: do not treat acute dystonia as tardive dyskinesia. Tardive dyskinesia emerges after months of exposure, is choreoathetoid and orobuccolingual, worsens with anticholinergics, and is treated with a VMAT2 inhibitor.
• Botulinum toxin is first line for focal/segmental dystonia; oral agents and DBS are for generalized or refractory disease.